nach oben

Current Osteoporosis Reports

Erschienen in:

01.04.2016 | Secondary Causes of Osteoporosis (SJ Warden, Section Editor)

Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics—a Review

verfasst von: Sandra J. Petty, Helen Wilding, John D. Wark

Erschienen in: Current Osteoporosis Reports | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

The increased rate of fractures associated with epilepsy has been long recognised but remains incompletely understood. Study quality and study results have varied, with some but not all studies showing bone diseases including osteoporosis and/or osteomalacia, and a high prevalence of vitamin D insufficiency and deficiency are also noted. Falls risk can also be higher in patients with epilepsy taking anti-epileptic medications, potentially leading to fracture. Larger research collaborations are recommended to further advance understanding in this field, particularly to examine underlying genetic and pharmacogenomic associations of epilepsy and anti-epileptic medication usage and its association with bone diseases and fractures, as well as further investigation into optimal management of bone health in epilepsy.

Kruse R. Osteopathies, calcium- and vitamin D metabolism errors during anti-epileptic long term therapy. Bibl Psychiatr. 1975;151:114–43.PubMed

Shen C, Chen F, Zhang Y, Guo Y, Ding M. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone. 2014;64:246–53. doi:10.1016/j.bone.2014.04.018.PubMedCrossRef

Ali II, Schuh L, Barkley GL, Gates JR. Antiepileptic drugs and reduced bone mineral density. Epilepsy and Behavior. 2004;5(3):296–300.PubMedCrossRef

Fife TD, Blum D, Fisher RS. Measuring the effects of antiepileptic medications on balance in older people. Epilepsy Res. 2006;70(2–3):103–9. doi:10.1016/j.eplepsyres.2006.03.004.PubMedCrossRef

WHO Study Group, Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis International. 1994;4(6):368–81.CrossRef

Kanis JA, McCloskey EV, Johansson H, Oden A, Melton 3rd LJ, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467–75. doi:10.1016/j.bone.2007.11.001.PubMedCrossRef

Elliott ME, Binkley N. Evaluation and measurement of bone mass. Epilepsy & Behavior. 2004;5(Suppl2):S16–23. doi:10.1016/j.yebeh.2003.11.027.CrossRef

Kanis J. Assessment of osteoporosis at the primary health care level. Sheffield: World Health Organization; 2007.

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.

10.

Salimipour H, Kazerooni S, Seyedabadi M, Nabipour I, Nemati R, Iranpour D, et al. Antiepileptic treatment is associated with bone loss: difference in drug type and region of interest. Journal of Nuclear Medicine Technology. 2013;41(3):208–11.PubMedCrossRef

11.

Pickrell WO, Lacey AS, White CP, Rees MI, Natarajan J. Fractures in people with a diagnosis of epilepsy: a population based study. Epilepsia2014. 29–30.

12.

Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol. 2010;23(2):164–9. doi:10.1097/WCO.0b013e32833735e7.PubMedCrossRef

13.

Arora SK, Bubb C, Karam J, McFarlane SI. Expanding use of anti-epileptic therapy: implications on bone disease. Therapy. 2007;4(1):79–89.CrossRef

14.

Beerhorst K, van der Kruijs SJ, Verschuure P, Tan IY, Aldenkamp AP. Bone disease during chronic antiepileptic drug therapy: general versus specific risk factors. Journal of the Neurological Sciences. 2013;331(1–2):19–25. doi:10.1016/j.jns.2013.05.005.PubMedCrossRef

15.

Gissel T, Poulsen CS, Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin Drug Saf. 2007;6(3):267–78.PubMedCrossRef

16.

Hahn TJ. Bone complications of anticonvulsants. Drugs. 1976;12(3):201–11.PubMedCrossRef

17.

Svalheim S, Roste LS, Nakken KO, Tauboll E. Bone health in adults with epilepsy. Acta Neurologica Scandinavica. 2011;191:89–95. doi:10.1111/j.1600-0404.2011.01551.x.PubMedCrossRef

18.

Khanna S, Pillai KK, Vohora D. Insights into liaison between antiepileptic drugs and bone. Drug Discov Today. 2009;14(7–8):428–35. doi:10.1016/j.drudis.2009.01.004.PubMedCrossRef

19.

Miziak B, Blaszczyk B, Chroscinska-Krawczyk M, Danilkiewicz G, Jagiello-Wojtowicz E, Czuczwar SJ. The problem of osteoporosis in epileptic patients taking antiepileptic drugs. Expert Opin Drug Saf. 2014;13(7):935–46. doi:10.1517/14740338.2014.919255.PubMedCrossRef

20.

Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol. 2007;14(4):196–200.PubMedCrossRef

21.

Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F. Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg. 2010;112(1):1–10. doi:10.1016/j.clineuro.2009.10.011.PubMedCrossRef

22.

Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy & behavior : E&B. 2004;5 Suppl 2:S3–15. doi:10.1016/j.yebeh.2003.11.026.CrossRef

23.

Petty SJ, Hill KD, Haber NE, Paton LM, Lawrence KM, Berkovic SF, et al. Balance impairment in chronic antiepileptic drug users: a twin and sibling study. Epilepsia. 2010;51(2):280–8. doi:10.1111/j.1528-1167.2009.02254.x.PubMedCrossRef

24.•

Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27. doi:10.1111/j.1528-1167.2012.03671.x. An important review for neurologists and prescribers of enzyme-inducing AEMs and the multiple associated comorbidities.PubMedCrossRef

25.

Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta neurologica Scandinavica 1999.

26.

Latorre H, Kenny FM. High dosage intravenous calcium therapy for osteoporosis and osteomalacia in anticonvulsant therapy with hypomobilization. Pediatrics. 1974;53(1):100–5.PubMed

27.

Lidgren L, Nilsson BE, Walloe A. Bone mineral content in epileptics. Calcified Tissue International. 1979;28(2):99–102.PubMedCrossRef

28.

Nilsson OS, Lindholm TS, Elmstedt E, Lindback A, Lindholm TC. Fracture incidence and bone disease in epileptics receiving long-term anticonvulsant drug treatment. Arch Orthop Trauma Surg. 1986;105(3):146–9.PubMedCrossRef

29.

Murchison LE, Bewsher PD, Chesters M. Effects of anticonvulsants and inactivity on bone disease in epileptics. Postgraduate Medical Journal. 1975;51(1):18–21.PubMedPubMedCentralCrossRef

30.

Weinstein RS, Bryce GF, Sappington LJ. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. Journal of Clinical Endocrinology and Metabolism. 1984;58(6):1003–9.PubMedCrossRef

31.

Petty S. Epilepsy and bone health. Neurology Asia. 2011;16(1):63–4.

32.

Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol. 2001;58(9):1369–74.PubMedCrossRef

33.

Ahmad BS, Hill KD, O’Brien TJ, Gorelik A, Habib N, Wark JD. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology. 2012;79(2):145–51.CrossRef

34.

Souverein P, Webb D, Weil J, Van Staa T, Egberts A. Use of antiepileptic drugs and risk of fractures: case–control study among patients with epilepsy. Neurology. 2006;66(9):1318–24. doi:10.1212/01.wnl.0000210503.89488.88.PubMedCrossRef

35.

Stephen LJ, McLellan AR, Harrison JH, Shapiro D, Dominiczak MH, Sills GJ, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure. 1999;8(6):339–42.PubMedCrossRef

36.

Wark JD, Larkins RG, Perry-Keene D, Peter CT, Ross DL, Sloman JG. Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxy-vitamin D. Clin Endocrinol (Oxf). 1979;11(3):267–74.CrossRef

37.

Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y, et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001;57(3):445–9.PubMedCrossRef

38.

Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127(2):256–62.PubMedCrossRef

39.

Cheah J, Stacpoole S, Heaney D, Duncan J. Are we measuring the bone health of epilepsy patients? Rheumatology. 2010;49:i84.

40.

Adler R, Semla T, Cunningham F, Pogach L. Potential under-treatment of male veterans with or at risk for osteoporotic fractures. J Bone Mineral Res 2010. S473.

41.

Tohill C. A study into the possible link between anti-epileptic drugs and the risk of fractures in Muckamore Abbey Hospital. Journal of Intellectual and Developmental Disability. 1997;22(4):281–92. doi:10.1080/13668259700033501.CrossRef

42.

Lyngstad-Brechan MA, Tauboll E, Nakken KO, Gjerstad L, Godang K, Jemtland R, et al. Reduced bone mass and increased bone turnover in postmenopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest. 2008;68(8):759–66. doi:10.1080/00365510802233442.PubMedCrossRef

43.

Beerhorst K, Tan IY, De Krom M, Verschuure P, Aldenkamp AP. Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy. Acta Neurologica Scandinavica. 2013;128(4):273–80. doi:10.1111/ane.12118.PubMedCrossRef

44.

Beerhorst K, Tan J, Tan IY, Verschuure P, Aldenkamp AP. Dual-energy X-ray absorptiometry versus quantitative ultrasonography in diagnosing osteoporosis in patients with refractory epilepsy and chronic antiepileptic drug use. Ther. 2013;5(2):59–66. doi:10.1177/1759720X13475851.

45.

Vestergaard P. Changes in bone turnover, bone mineral and fracture risk induced by drugs used to treat epilepsy. Curr Drug Saf. 2008;3(3):168–72.PubMedCrossRef

46.

Roohi F, Fox A. Burst fracture of the first lumbar vertebra and conus-cauda syndrome complicating a single convulsive seizure: a challenge of diagnosis in the emergency department. Journal of Emergency Medicine. 2006;31(4):381–5.PubMedCrossRef

47.

Napier R, Nolan PC. Diagnosis of vertebral fractures in post-ictal patients. Emergency Medicine Journal. 2011;28(2):169–70.PubMedCrossRef

48.

Copuroglu C, Ozcan M, Dulger H, Yalniz E. Late-diagnosed bilateral intertrochanteric femur fracture during an epileptic seizure. Ulus Travma Acil Cerrahi Derg. 2012;18(1):92–4. doi:10.5505/tjtes.2011.76402.PubMedCrossRef

49.

Alenazi B, Rana AQ, Vaid HM. The importance of imaging for status epilepticus patients to rule out fractures—a case report. Journal of Taibah University Medical Sciences. 2013;8(2):120–2.CrossRef

50.

Caffarelli C, Hayek J, Tomai Pitinca MD, Nuti R, Gonnelli S. A comparative study of dual-X-ray absorptiometry and quantitative ultrasonography for the evaluating bone status in subjects with Rett syndrome. Calcified Tissue International. 2014;95(3):248–56. doi:10.1007/s00223-014-9888-x.PubMedCrossRef

51.

Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, et al. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone. 2013;52(2):557–61. doi:10.1016/j.bone.2012.09.028.PubMedCrossRef

52.

Kanis J, Johnell O, Gullberg B, Allander E, Elffors L, Ranstam J, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporosis International. 1999;9(1):45–54.PubMedCrossRef

53.

Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure. 2013;22(1):37–42. doi:10.1016/j.seizure.2012.10.002.PubMedCrossRef

54.

Abrahamsen B, Brixen K. Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk. Osteoporosis International. 2009;20(4):585–97. doi:10.1007/s00198-008-0711-2.PubMedCrossRef

55.

Annegers JF, Melton 3rd LJ, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia. 1989;30(3):348–55.PubMedCrossRef

56.

Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332(12):767–73. doi:10.1056/NEJM199503233321202.PubMedCrossRef

57.

Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia. 2002;43(7):768–72.PubMedCrossRef

58.

Lapi F, Simonetti M, Michieli R, Pasqua A, Brandi ML, Frediani B, et al. Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone. 2012;50(1):85–90. doi:10.1016/j.bone.2011.09.048.PubMedCrossRef

59.

Tsiropoulos I, Andersen M, Nymark T, Lauritsen J, Gaist D, Hallas J. Exposure to antiepileptic drugs and the risk of hip fracture: a case–control study. Epilepsia. 2008;49(12):2092–9. doi:10.1111/j.1528-1167.2008.01640.x.PubMedCrossRef

60.•

Beerhorst K, Schouwenaars FM, Tan IY, Aldenkamp AP. Epilepsy: fractures and the role of cumulative antiepileptic drug load. Acta Neurologica Scandinavica. 2012;125(1):54–9. doi:10.1111/j.1600-0404.2011.01509.x. Introduces the concept of cumulative AEM load and effects on bone health.PubMedCrossRef

61.

Petty SJ, Paton LM, O’Brien TJ, Makovey J, Erbas B, Sambrook P, et al. Effect of antiepileptic medication on bone mineral measures. Neurology. 2005;65(9):1358–63.PubMedCrossRef

62.

Badcock LJ, Smith JA, Price T, Mulherin DM. Bone mineral density in post-menopausal women on anticonvulsant therapy. Journal of the Irish Colleges of Physicians and Surgeons. 2000;29(3):138–40.

63.

Petty SJ, O’Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporosis International. 2007;18(2):129–42.PubMedCrossRef

64.

Moro-Alvarez MJ, Diaz Curiel M, de la Piedra C, Marinoso ML, Carrascal MT. Bone disease induced by phenytoin therapy: clinical and experimental study. Eur Neurol. 2009;62(4):219–30. doi:10.1159/000229309.PubMedCrossRef

65.••

Pack AM. Genetic variation may clarify the relationship between epilepsy, antiepileptic drugs, and bone health. European Journal of Neurology. 2011;18(1):3–4. doi:10.1111/j.1468-1331.2010.03137.x. A review of new studies examining vitamin D receptor genetic variation and the association between epilepsy and bone health.PubMedCrossRef

66.

Hamed SA, Moussa EM, Youssef AH, Abd ElHameed MA, NasrEldin E. Bone status in patients with epilepsy: relationship to markers of bone remodeling. Front Neurol. 2014;5:142. doi:10.3389/fneur.2014.00142.PubMedPubMedCentralCrossRef

67.

Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj FG. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58(9):1348–53.PubMedCrossRef

68.

Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy & Behavior. 2004;5 Suppl 2:S36–40.CrossRef

69.

Lee R, Lyles K, Sloane R, Colon-Emeric C. The association between newer anticonvulsants and bone mineral density. J Bone Mineral Res 2011.

70.

Koo DL, Joo EY, Kim D, Hong SB. Effects of levetiracetam as a monotherapy on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2013;104(1–2):134–9. doi:10.1016/j.eplepsyres.2012.09.002.PubMedCrossRef

71.

Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology. 2008;71(10):723–30. doi:10.1212/01.wnl.0000324919.86696.a9.PubMedPubMedCentralCrossRef

72.

Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther. 2011;3(5):235–43. doi:10.1177/1759720X11410769.

73.

Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586–93. 8p.PubMedPubMedCentralCrossRef

74.

Guo CY, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia. 2001;42(9):1141–7.PubMedCrossRef

75.

Akin RI, Okutan V, Sarici U, Altunbaş A, Gökçay E. Evaluation of bone mineral density in children receiving antiepileptic drugs. Pediatric Neurology. 1998;19(2):129–31.PubMedCrossRef

76.

Chou IJ, Lin KL, Wang HS, Wang CJ. Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy. Acta Paediatr Taiwan. 2007;48(6):317–22.PubMed

77.

Baek JH, Seo YH, Kim GH, Kim MK, Eun BL. Vitamin D levels in children and adolescents with antiepileptic drug treatment. Yonsei Med J. 2014;55(2):417–21. doi:10.3349/ymj.2014.55.2.417.PubMedPubMedCentralCrossRef

78.

Gniatkowska-Nowakowska A. Fractures in epilepsy children. Seizure. 2010;19(6):324–5. doi:10.1016/j.seizure.2010.04.013.PubMedCrossRef

79.

Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid–base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009;68(5):655–61. doi:10.1111/j.1365-2125.2009.03521.x.PubMedPubMedCentralCrossRef

80.

Bergqvist AG, Schall JI, Stallings VA, Zemel BS. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr. 2008;88(6):1678–84. doi:10.3945/ajcn.2008.26099.PubMedCrossRef

81.

Groesbeck DK, Bluml RM, Kossoff EH. Long-term use of the ketogenic diet in the treatment of epilepsy. Developmental Medicine and Child Neurology. 2006;48(12):978–81.PubMedCrossRef

82.

Andress DL, Ozuna J, Tirschwell D, Grande L, Johnson M, Jacobson AF, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol. 2002;59(5):781–6.PubMedCrossRef

83.

McGrother CW, Donaldson MM, Clayton D, Abrams KR, Clarke M. Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) study. Osteoporosis International. 2002;13(1):89–96. doi:10.1007/s198-002-8343-6.PubMedCrossRef

84.

Broulik P, Kragstrup J, Mosekilde L, Melsen F. Osteon cross-sectional size in the iliac crest: variation in normals and patients with osteoporosis, hyperparathyroidism, acromegaly, hypothyroidism and treated epilepsia. Acta Pathol Microbiol Immunol Scand [A]. 1982;90(5):339–44.

85.

Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res. 2004;50(1):93–7.PubMedCrossRef

86.

Bostancioǧlu M, Öner N, Küçükuǧurluoǧlu Y, Kaya M, Aladaǧ N, Çeltik C, et al. Does valproate therapy decrease the bone mineral density in one-year follow-up in children? Trakya Universitesi Tip Fakultesi Dergisi. 2009;26(1):24–8.

87.

Feldkamp J, Becker A, Witte OW, Scharff D, Scherbaum WA. Long-term anticonvulsant therapy leads to low bone mineral density—evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells. Exp Clin Endocrinol Diabetes. 2000;108(1):37–43.PubMed

88.

Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy & Behavior. 2004;5 Suppl 2:S24–9.CrossRef

89.

Fraser LA, Burneo JG, Fraser JA. Enzyme-inducing antiepileptic drugs and fractures in people with epilepsy: a systematic review. Epilepsy Res. 2015;116:59–66. doi:10.1016/j.eplepsyres.2015.07.003.PubMedCrossRef

90.

Voudris KA, Attilakos A, Katsarou E, Garoufi A, Dimou S, Skardoutsou A, et al. Early alteration in bone metabolism in epileptic children receiving carbamazepine monotherapy owing to the induction of hepatic drug-metabolizing enzymes. J Child Neurol. 2005;20(6):513–6.PubMed

91.

Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure. 2008;17(2):181–6. doi:10.1016/j.seizure.2007.11.020.PubMedCrossRef

92.

Babacan O, Karaoglu A, Vurucu S, Yesilyurt O, Yesilkaya E, Cayci T et al. May long tem oxcarbazepine therapy be leading to secondary hyperparathyroidism? Eur J Paediatric Neurology 2011. S90.

93.

Hamed SA. Influences of bone and mineral metabolism in epilepsy. Expert Opin Drug Saf. 2011;10(2):265–80. doi:10.1517/14740338.2011.534455.PubMedCrossRef

94.

Kruse K, Bartels H, Ziegler R, Dreller E, Kracht U. Parathyroid function and serum calcitonin in children receiving anticonvulsant drugs. Eur J Pediatr. 1980;133(2):151–6.PubMedCrossRef

95.

Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002;43(12):1488–92.PubMedCrossRef

96.

Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol. 2008;83:305–28. doi:10.1016/S0074-7742(08)00018-4.PubMedCrossRef

97.

Pack AM. Antiepileptic drugs and bone disease. Clinical Reviews in Bone and Mineral Metabolism. 2004;2(2):159–65.CrossRef

98.

Pack AM. The impact of long-term antiepileptic drug use on bone health. Advanced Studies in Medicine. 2005;5(6 C):S567–S71.

99.

Kruse K. On the pathogenesis of anticonvulsant-drug-induced alterations of calcium metabolism. Eur J Pediatr. 1982;138(3):202–5.PubMedCrossRef

100.

Kruse K, Suss A, Busse M, Schneider P. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr. 1987;111(1):57–63.PubMedCrossRef

101.

Mosekilde L, Hansen HH, Christensen MS, Lund B, Sorensen OH, Melsen F, et al. Fractional intestinal calcium absorption in epileptics on anticonvulsant therapy. Short-term effect of 1,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol. Acta Med Scand. 1979;205(5):405–9.PubMed

102.

Elliott JO, Jacobson MP, Haneef Z. Homocysteine and bone loss in epilepsy. Seizure. 2007;16(1):22–34.PubMedCrossRef

103.

Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005;115(1):177–86. doi:10.1172/JCI21867.PubMedPubMedCentralCrossRef

104.

Kulak CA, Borba VZ, Bilezikian JP, Silvado CE, Paola L, Boguszewski CL. Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs. Arq Neuropsiquiatr. 2004;62(4):940–8.PubMedCrossRef

105.

Phabphal K, Geater A. The association between BsmI polymorphism and risk factors for atherosclerosis in patients with epilepsy taking valproate. Seizure. 2013;22(9):692–7. doi:10.1016/j.seizure.2013.05.003.PubMedCrossRef

106.

Phabphal K, Geater A, Limapichart K, Sathirapanya P, Setthawatcharawanich S, Witeerungrot N, et al. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin. Epilepsia. 2013;54(2):249–55. doi:10.1111/epi.12049.PubMedCrossRef

107.

De Miguel-Elízaga I, Martínez-Villanueva M, Villegas-Martínez I, Carrasco-Torres R, Martínez-Ruíz A, Cebreiros-López I, et al. Bone loss associated with use of antiepileptic drugs and genetic predisposition. Clinical Chemistry and Laboratory Medicine. 2015;53:S445.

108.

Lambrinoudaki I, Kaparos G, Armeni E, Alexandrou A, Damaskos C, Logothetis E, et al. BsmI vitamin D receptor’s polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy. European Journal of Neurology. 2011;18(1):93–8. doi:10.1111/j.1468-1331.2010.03103.x.PubMedCrossRef

109.

de Abreu DA F, Eyles D, Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009;34 Suppl 1:S265–77. doi:10.1016/j.psyneuen.2009.05.023.CrossRef

110.

Jiang P, Zhu WY, He X, Tang MM, Dang RL, Li HD, et al. Association between vitamin D receptor gene polymorphisms with childhood temporal lobe epilepsy. Int J Environ Res Public Health. 2015;12(11):13913–22. doi:10.3390/ijerph121113913.PubMedPubMedCentralCrossRef

111.••

Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, et al. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy—antiepileptic drug and osteoporosis prevention trial. Epilepsia. 2013. doi:10.1111/epi.12351. Treatment studies—calcium and vitamin D alone do not appear to prevent fractures compared to bisphosphonate.PubMed

112.••

Dussault P, Davis Jr S, Lazzari AA. The effect of calcium and vitamin D on bone loss in an epileptic population. Arthritis and rheumatism 2012. p. S842. Treatment studies—calcium and vitamin D alone do not appear to prevent fractures compared to bisphosphonate.

113.

Pepe I, Campisi G, Scozzari F, Napoli N, Rini G, Di Fede G. Bone loss caused by anticonvulsants: BMD improvement using strontium ranelate. J Bone Mineral Res 2011.

114.

Vestergaard P. Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurologica Scandinavica. 2005;112(5):277–86.PubMedCrossRef

115.

Davidson DL, Macdonald S. The costs of trauma caused by seizures: can they be reduced? Seizure. 2002;11(5):344–7.PubMedCrossRef

116.

Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurologica Scandinavica. 2005;111(4):225–8.PubMedCrossRef

117.

Elliott JO, Seals BF, Jacobson MP. Osteoprotective knowledge in a multiethnic epilepsy population. J Neurosci Nurs. 2008;40(1):14–24. 39.PubMedCrossRef

118.

Elliott JO, Seals BF, Jacobson MP. Use of the Precaution Adoption Process Model to examine predictors of osteoprotective behavior in epilepsy. Seizure. 2007;16(5):424–37.PubMedCrossRef

119.

Elliott JO, Jacobson MP. Bone loss in epilepsy: barriers to prevention, diagnosis, and treatment. Epilepsy & Behavior. 2006;8(1):169–75.CrossRef

120.

Gross RA, Gidal BE, Pack AM. Patient page. Antiseizure drugs and reduced bone density. Neurology. 2004;62(11):E24–5.PubMedCrossRef

121.

Nakken KO, Tauboll E. Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf. 2010;9(4):561–71. doi:10.1517/14740331003636475.PubMedCrossRef

122.

Harijan P, Khan A, Hussain N. Vitamin D deficiency in children with epilepsy: do we need to detect and treat it? Journal of Pediatric Neurosciences. 2013;8(1):5–10. doi:10.4103/1817-1745.111413.PubMedPubMedCentralCrossRef

123.

Marcuccilli CJ. Vitamin D, deficiency in pediatric epilepsy. Journal of Pediatric Epilepsy. 2013;2(3):199–208.

124.

Teagarden DL, Meador KJ, Loring DW. Low vitamin D levels are common in patients with epilepsy. Epilepsy Res. 2014;108(8):1352–6. doi:10.1016/j.eplepsyres.2014.06.008.PubMedPubMedCentralCrossRef

125.

Cloyd J, Hauser W, Towne A, Ramsay R, Mattson R, Gilliam F, et al. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006;68 Suppl 1:S39–48.PubMedCrossRef

126.

Cohen A, Lancman M, Mogul H, Marks S, Smith K. Strategies to protect bone mass in the older patient with epilepsy. Geriatrics. 1997;52(8):5–8. 81.

127.

Ziemba KS, Noe KH. Treatment of epilepsy in postmenopausal women. Aging Health. 2010;6(1):87–96.CrossRef

128.

Khan SA. Women, epilepsy and anti-epileptic drugs. Neurosciences. 2004;9(2):74–9.PubMed

129.

Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005;46 Suppl 9:117–24.PubMedCrossRef

130.

Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet. 2011;284(3):749–55. doi:10.1007/s00404-011-1936-4.PubMedCrossRef

131.

Adis Medical Writers. Be aware of the potential effects of menopause on epilepsy and its treatment. Drugs and Therapy Perspectives. 2015;31(5):161–3.CrossRef

132.

Homann B, Plaschg A, Grundner M, Haubenhofer A, Griedl T, Ivanic G, et al. The impact of neurological disorders on the risk for falls in the community dwelling elderly: a case-controlled study. BMJ Open. 2013;3(11), e003367. doi:10.1136/bmjopen-2013-003367.PubMedPubMedCentralCrossRef

133.

Stolze H, Klebe S, Zechlin C, Baecker C, Friege L, Deuschl G. Falls in frequent neurological diseases—prevalence, risk factors and aetiology. J Neurol. 2004;251(1):79–84. doi:10.1007/s00415-004-0276-8.PubMedCrossRef

134.

Lee L, Wagner M, Wu B. Epilepsy patients should receive DXA screening. Epilepsy Currents. 2013;13:92–3.CrossRef

135.

Drezner MK. Treatment of anticonvulsant drug-induced bone disease. Epilepsy & Behavior. 2004;5 Suppl 2:S41–7.CrossRef

136.

Kurth C, Keller L, Steinhoff BJ. Determination of alkaline phosphatase without isozymes is not appropriate for monitoring of increased bonemass turnover in patients on inducing antiepileptic drugs. Epilepsia. 2009;50:49.

137.

Elliott JO. Possible methods for the prevention of bone loss in persons with epilepsy. Expert rev. 2009;9(6):797–812. doi:10.1586/ern.09.35.

138.

Johnston CA, Crawford PM. Anti-epileptic drugs and hormonal treatments. Current Treatment Options in Neurology. 2014;16(5):288. doi:10.1007/s11940-014-0288-3.PubMedCrossRef

139.

Lazzari AA, Dussault P, Davis S. Improvement of treatment decisions in epileptic patients by performing lateral vertebral assessment (LVA). Journal of Clinical Densitometry. 2010;13:118.CrossRef

Titel: Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics—a Review
verfasst von: Sandra J. Petty
Helen Wilding
John D. Wark
Publikationsdatum: 01.04.2016
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 2/2016
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-016-0302-7

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen